Catalog4 refs
Servodutide
MetabolicResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
Obesity/NAFLD research, GLP-1/glucagon dual agonism, Liver-fat reduction studies, Weight-management trials. Long-acting dual agonist supporting once-weekly dosing.
Primary Uses
Obesity/NAFLD research
GLP-1/glucagon dual agonism
Liver-fat reduction studies
Weight-management trials
Protocol Reference
Dose
0.3mg-6mg weekly (titrated). 1x Weekly titration: Week 1-4: 0.3mg, Week 5-8: 0.6mg, Week 9-12: 1.2mg, Week 13-16: 2.4mg, Week 17-20: 3.6mg, Week 21-24: 4.8mg, Week 25+: 6mg. 2x Weekly titration: Week 1-4: 0.15mg, Week 5-8: 0.3mg, Week 9-12: 0.6mg, Week 13-16: 1.2mg, Week 17-20: 1.8mg, Week 21-24: 2.4mg, Week 25+: 3mg.
Frequency
Once or twice weekly, same day(s) each week
Half-life
Long-acting; supports once-weekly dosing
Route
Subcutaneous
Research References· 4
Research Models
Humancompanion animals
Also in Metabolic